Eris Sustainability Profile
Eris, officially known as Eris Lifesciences, is a prominent player in the Indian pharmaceutical industry, headquartered in India. Founded in 2007, the company has rapidly established itself as a leader in the development and marketing of high-quality generic medications, particularly in the therapeutic areas of diabetes, cardiovascular health, and respiratory diseases. With a strong operational presence across India and expanding international markets, Eris is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of formulations that are distinguished by their efficacy and affordability, catering to the needs of healthcare professionals and patients alike. Eris has achieved significant milestones, including a robust portfolio of over 100 products and a growing market share, positioning itself as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Eris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eris's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eris's reported carbon emissions
Eris Lifesciences Limited, headquartered in India, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available at this time. As a result, Eris's climate commitments and initiatives remain unclear, and there is no information regarding any emissions inherited from a parent or related organization. The company has not established any Science-Based Targets Initiative (SBTi) targets or other significant climate initiatives that are publicly documented. In the context of the pharmaceutical industry, where sustainability and carbon reduction are increasingly important, Eris may need to develop and communicate its climate strategy to align with industry standards and expectations.
How Carbon Intensive is Eris's Industry?
How Carbon Intensive is Eris's Location?
Eris's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eris has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
